Heptotal Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid utilized primarily in the management of various hepatobiliary disorders. It is indicated for the dissolution of cholesterol gallstones in patients with a functioning gallbladder and for the treatment of primary biliary cholangitis (PBC), a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. Ursodeoxycholic Acid exerts its therapeutic effect by reducing the cholesterol content of bile, thereby decreasing cholesterol saturation and promoting the gradual dissolution of cholesterol-rich gallstones. Additionally, it improves bile flow and exerts cytoprotective effects on hepatocytes, mitigating cholestasis and liver inflammation. Heptotal Tablet is administered orally, with dosage tailored according to the specific condition and patient response, typically ranging from 10 to 15 mg/kg/day divided into two or three doses. Common adverse effects are generally mild and include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Caution is advised in patients with complete biliary obstruction or advanced liver disease. Regular monitoring of liver function tests is recommended during therapy to assess efficacy and detect potential hepatotoxicity. Heptotal Tablet should be used under medical supervision to ensure optimal therapeutic outcomes.